Ultragenyx Pharmaceutical Inc.
About 1,000workers
SEC filingAnnounced
Ultragenyx Pharmaceutical Inc. tells investors it plans to cut about 1,000 positions
- Industry
- Biotech
- Filed with the SEC
- November 3, 2026
- Whose workers
- Scope not stated
- In the report for
- November 4, 2026
What happened
Ultragenyx Pharmaceutical Inc. told the SEC it plans to reduce its workforce by about 1,000 positions.
Sources
SEC EDGAR · SEC filing · Nov 3, 2026
Savings actions include: • Reducing headcount by approximately 20%, resulting in a revised workforce of approximately 1,000 employees • Completing wind-down of all ongoing studies for GTX-102 for Angelman syndrome • Terminating UX701 for Wilson disease based on not achieving study goals • Reducing expenses across the company, including reduction of real estate footprint In addition to executing these critical expense reductions, the company is focused on driving successful launches for GENGLYCOS and FAYUVI and continuing to grow current product revenues.
Read the sourceSEC EDGAR · SEC filing · Nov 3, 2026
On November 3, 2026, the Company announced a restructuring plan to reduce expenses (the “Restructuring”).
Read the source